Litigation Initiated by Capricor Therapeutics Regarding Deramiocel Commercialization Agreements

Capricor Therapeutics 就 Deramiocel 商業化協議提起訴訟

May 8, 2026, 18:32
JapanHealth

Introduction

Capricor Therapeutics has commenced legal proceedings against Nippon Shinyaku and its subsidiary, NS Pharma, concerning the market launch of a Duchenne muscular dystrophy cell therapy.

Capricor Therapeutics 已對 Nippon Shinyaku 及其子公司 NS Pharma 採取法律程序，涉及一款杜氏肌肉萎縮症細胞療法的上市事宜。

Main Body

The litigation, filed within the New Jersey state court system, centers upon allegations of professional negligence regarding the execution of marketing strategies for deramiocel. Capricor Therapeutics asserts that the defendants failed to adhere to established launch preparations, thereby compromising the therapy's viability.

該訴訟已提交至紐澤西州法院系統，核心在於指控對方在執行 deramiocel 的行銷策略時存在專業過失。Capricor Therapeutics 主張被告未能遵守既定的上市準備工作，從而損害了該療法的可行性。

Central to the dispute is a purported systemic failure within the pricing architecture of the exclusive distribution agreement. It is alleged that a critical deficiency in the pricing formula—disclosed by Nippon Shinyaku and NS Pharma in March 2025—renders the treatment economically non-viable for patients utilizing Medicare, Medicaid, and private insurance. Specifically, the current framework links Medicare reimbursement to the price Capricor charges NS Pharma. Should this structure persist, healthcare providers would ostensibly receive reimbursements insufficient to cover the acquisition and administration costs of the pharmaceutical agent, effectively precluding patient access.

爭議的焦點在於獨家分銷協議的定價結構據稱存在系統性失敗。指控稱 Nippon Shinyaku 和 NS Pharma 在 2025 年 3 月披露的定價公式存在關鍵缺陷，導致使用 Medicare、Medicaid 及私人保險的患者在經濟上無法承擔該治療。具體而言，目前的框架將 Medicare 的核銷金額與 Capricor 向 NS Pharma 收取的價格掛鉤。若此結構持續，醫療服務提供者收到的核銷金額顯然不足以支付藥劑的採購與管理成本，實際上將阻礙患者獲取治療。

Conclusion

The matter remains under judicial review as Capricor seeks to rectify the pricing discrepancies and address the alleged failure in commercial execution.

由於 Capricor 尋求修正定價差異並解決指稱的商業執行失敗問題，該事項目前仍處於司法審查階段。

Vocabulary Learning

The Architecture of 'Hedge-Precision' in Legalistic English

To bridge the gap from B2 to C2, one must move beyond simple modality (e.g., maybe, perhaps) and master Epistemic Distancing. In this text, the author employs a sophisticated layer of professional detachment to describe high-stakes accusations without committing to the factual truth of those accusations.

◈ The Nuance of Purported vs. Alleged

Observe the strategic deployment of these adjectives:

  • "...a purported systemic failure..."
  • *"...the alleged failure in commercial execution."

At a C2 level, you must recognize that these are not mere synonyms for 'claimed.' Purported often suggests a specific representation or a 'pretended' state that is being challenged, while alleged is the gold standard for legal non-committal, shielding the writer from libel by attributing the claim to another party.

◈ The 'Ostensibly' Pivot

"...healthcare providers would ostensibly receive reimbursements insufficient..."

Ostensibly is a high-leverage C2 adverb. It functions as a linguistic signal that the surface appearance (the pricing formula) contradicts the intended or actual reality. It allows the writer to describe a hypothetical outcome while simultaneously casting doubt on the legitimacy of the current framework. It transitions the narrative from a statement of fact to a critical analysis of a flawed system.

◈ Syntactic Density: The Nominalization Chain

C2 mastery is characterized by the ability to condense complex actions into noun phrases to maintain a formal, objective tone. Consider this sequence: Pricing architecture →\rightarrow Critical deficiency →\rightarrow Commercial execution

Instead of saying "They failed to execute the commerce," the text uses "failure in commercial execution." This nominalization strips the sentence of 'actors' and replaces them with 'concepts,' which is the hallmark of academic and judicial discourse. It shifts the focus from who did it to what happened.

Vocabulary Learning

negligence (n.)
Failure to provide the care or attention that a reasonable person would provide.
Example:The court found the hospital's negligence led to the patient's worsening condition.
execution (n.)
The act of carrying out or performing a task.
Example:The successful execution of the marketing strategy resulted in higher sales.
viability (n.)
The ability of something to survive, succeed, or be effective.
Example:The project's viability was questioned after the funding cuts.
purported (adj.)
Claimed or asserted, but not proven or verified.
Example:The purported benefits of the new drug were disputed by experts.
systemic (adj.)
Relating to or affecting an entire system.
Example:The company faced systemic issues in its supply chain.
deficiency (n.)
A lack or shortage of something necessary.
Example:A deficiency in the pricing formula caused significant losses.
architecture (n.)
The conceptual structure and design of a system.
Example:The pricing architecture was designed to ensure fairness.
exclusive (adj.)
Limited to a particular person, group, or purpose.
Example:The exclusive distribution agreement granted sole rights to NS Pharma.
distribution (n.)
The act of delivering goods or services to consumers.
Example:The distribution network reached remote communities.
agreement (n.)
A negotiated contract or arrangement between parties.
Example:The agreement stipulated payment terms and delivery schedules.
non-viable (adj.)
Not capable of surviving or succeeding.
Example:The treatment was deemed non-viable for certain patients.
reimbursement (n.)
Payment made to cover incurred expenses.
Example:Reimbursement rates were lower than expected.
acquisition (n.)
The act of obtaining or purchasing something.
Example:The acquisition of the drug cost the company millions.
administration (n.)
The act of managing or delivering a service.
Example:Administration of the therapy required specialized training.
precluding (v.)
Preventing or making impossible.
Example:High costs preclude many patients from accessing the therapy.
rectify (v.)
To correct or fix a problem.
Example:The company aims to rectify pricing discrepancies.
discrepancies (n.)
Differences or inconsistencies between expected and actual values.
Example:The audit uncovered pricing discrepancies.
commercial (adj.)
Relating to business or commerce.
Example:Commercial execution was lacking in the launch plan.
allegations (n.)
Claims or accusations that are not yet proven.
Example:Allegations of negligence were filed against the company.
pricing (n.)
The setting of price levels for goods or services.
Example:The pricing of the drug was contested by insurers.
formula (n.)
A mathematical or systematic expression.
Example:The pricing formula was revised to improve fairness.
framework (n.)
An underlying structure or system of rules.
Example:The reimbursement framework guides payment decisions.
launch (n.)
The act of introducing a product or service to the market.
Example:The product launch was postponed due to regulatory delays.
preparations (n.)
The arrangements or steps taken before an event.
Example:Launch preparations included marketing and logistics.
Practice C2 words in a crossword→